Here's why the Polynovo (ASX:PNV) share price is rocketing 12% today

The company's shares are taking off on Tuesday.

The Polynovo Ltd (ASX: PNV) share price is racing ahead today following a positive business update from the company.

At the time of writing, the medical device company's shares are fetching for $1.53, up 12.50%. This means that its shares have clawed back the consecutive losses registered in the past week.

A drawing of a white rocket streaking up, indicating a surging share pirce movement

Image source: Getty Images

What did Polynovo announce?

In a statement to the ASX, Polynovo advised that its United States segment has experienced a strong start to the second quarter.

Sales for October and November have recorded a 133% increase to $4.66 million over the prior corresponding period ($1.99 million). The business noted that last month was particularly solid, equalling the record month of sales in July 2021.

The United States portfolio added 11 additional accounts since 30 September, bringing to the total to 146 accounts.

Across the United Kingdom, Ireland and Europe, Polynovo acknowledged the region has underperformed to expectations. A number of initiatives are being undertaken to improve the sales base along with its distributor network.

In Australia and New Zealand, the segment remains on track despite a temporary blip in the reduction of burn cases. Polynovo highlighted that more than 40% of all BTM use is now outside of burns.

Furthermore, an undisclosed number of large corporations have expressed their interest in bringing BTM to their retrospective markets. Polynovo stated that it is working to establish these relationships for FY22.

The company has also stepped up its recruitment drive as well as its international search for a new CEO. The board is confident of filling the position sometime within the first quarter of 2022.

Polynovo chair, David Williams commented:

There has been a significant uplift in intensity in all areas of the business in the last month. We are adding immediately significant scale to our US salesforce and some important new hires in the UK and other parts of the business.

Polynovo share price snapshot

Over the past 12 months, the Polynovo share price has continued its downward trend to post a 65% loss.

In comparison, the S&P/ASX 200 Healthcare (ASX: XHJ) sector has gained around 7.3% in the same time frame.

It's worth noting that Polynovo shares hit a multi-year low of $1.35 yesterday. This is a huge difference from when its shares were trading above the $4 mark in December 2020.

Based on today's price, Polynovo presides a market capitalisation of about $912.72 million and has approximately 661.39 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL vs Pro Medicus: Which ASX healthcare share is better?

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy…

Read more »